Sign In
Buy SGEN
$228.74
+0 (+0%)
At Close: Mar 12, 2024
7 Stocks To Buy To Bet on Underappreciated CEOs
06:30am, Friday, 10'th Sep 2021
We hear plenty of stories about overpaid CEOs. Here are seven stocks to buy whose CEOs aren't but still manage to deliver for shareholders.
3 Top Healthcare Stocks to Buy for September
06:30am, Friday, 10'th Sep 2021
Catalysts are on the horizon for these bargain stocks.
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
08:00am, Wednesday, 08'th Sep 2021
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced data and trials in progress from its diverse and growing portfolio of marketed and investigational therapies will be present
Which Biotech Stock Will Shock the Market in 2022?
10:40am, Friday, 27'th Aug 2021
Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?
Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
06:00am, Monday, 09'th Aug 2021
BOTHELL, Wash. & YANTAI, China--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. (9995.HK), a leading innovativ
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
03:12pm, Friday, 30'th Jul 2021
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
Seagen's (SGEN) CEO Clay Siegall on Q2 2021 Results - Earnings Call Transcript
11:18pm, Thursday, 29'th Jul 2021
Seagen's (SGEN) CEO Clay Siegall on Q2 2021 Results - Earnings Call Transcript
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
07:00pm, Thursday, 29'th Jul 2021
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 22.95% and 9.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Seagen (SGEN) Gets Regular Approval, Label Expansion for Padcev
01:12pm, Monday, 12'th Jul 2021
Seagen and Astellas' two sBLAs for Padcev get FDA approval for patients with locally advanced or metastatic urothelial cancer. The approval comes one month before the PDUFA date of Aug 17, 2021.
TOKYO and BOTHELL, Wash., July 9, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
This Risky Micro-Cap Could Pay Off Big
08:31am, Wednesday, 30'th Jun 2021
Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.
Seagen: Substantially More Growth For This Stalwart
10:14am, Sunday, 20'th Jun 2021
Despite its sizable capitalization, you can expect more upsides from Seagen due to many label expansions and novel therapeutic development programs. As a group, the three commercialized molecules (Adc
BOTHELL, Wash.--(BUSINESS WIRE)-- #ASCO2021--Seagen Announces Long-Term Results from Pivotal Trial in Patients with HER2-Positive Breast Cancer During the 2021 ASCO Annual Meeting
TOKYO and BOTHELL, Wash., May 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.
3 Biotech Stocks You'll Be Glad You Bought at These Prices
06:00am, Wednesday, 19'th May 2021
Their revenue prospects are the ticket to future share price performance.
